Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson
13 Novembro 2023 - 3:40PM
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announced
today with great sadness that Virgil Thompson, Director,
passed away unexpectedly on November 9, 2023. Mr. Thompson served
on our Board of Directors since we were formed in 2017 and was
previously on the Board of Directors of Promet Therapeutics, LLC,
our predecessor. He was 83 years old.
“We are all saddened by the sudden passing of
our friend and one of our founding board members, Virgil Thompson,”
commented Justin Yorke, Chairman of Processa’s Board of Directors.
“We are thankful for Virgil’s leadership, guidance and wisdom, and
we will remember him fondly. He will be greatly missed by the Board
and the whole Processa family.” Over his career Mr. Thompson’s
experiences included serving as an executive and/or director for
several biotechnology companies.
About Processa Pharmaceuticals,
Inc.
Processa is a clinical stage pharmaceutical
company focused on developing the Next Generation Chemotherapy
drugs to improve the safety and efficacy of cancer treatment. By
combining Processa’s novel oncology pipeline with proven
cancer-killing active molecules and the Processa Regulatory Science
Approach as well as experience in defining Optimal Dosage Regimens
for FDA approvals, Processa not only will be providing better
therapy options to cancer patients but also increase the
probability of FDA approval for its Next Generation Chemotherapy
drugs. Processa’s NGC drugs are modifications of existing
FDA-approved oncology drugs resulting in an alteration of the
metabolism and/or distribution of drugs while maintaining the
existing mechanisms of killing the cancer cells. Our approach to
drug development is based on more than 30 years of drug development
expertise to efficiently design and conduct clinical trials that
demonstrate a positive benefit/risk relationship. Using its proven
Regulatory Science Approach, we have experience defining the
Optimal Dosage Regimen using the principles of the FDA’s Project
Optimus Oncology initiative. The advantages of Processa’s Next
Generation Chemotherapy drugs are expected to include fewer
patients experiencing side effects that lead to dose
discontinuation; more significant cancer response; and a greater
number of patients who will benefit from each Next Generation
Chemotherapy drug. Currently in our pipeline are three Next
Generation Chemotherapy drugs: Next Generation Capecitabine
(PCS6422 and capecitabine to treat metastatic colorectal,
gastrointestinal, breast, pancreatic, and other cancers), Next
Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian,
breast, and other cancers), and Next Generation Irinotecan (PCS11T
to treat lung, colorectal, gastrointestinal, pancreatic, and other
cancers).
For more information, visit our website
at www.processapharma.com.
For More
Information:Investors:Bret ShapiroCORE
IRir@processapharma.com
Company Contact:Patrick Lin(925)
683-3218plin@processapharma.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024